))
Lung Cancer Edition: Top Headlines for Week of April 3, 2023
Manage episode 407442277 series 3560281
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.
Read the full coverage here:
Study reveals ‘paradigm shift’ in non-small cell lung cancer during past decade
Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer
Amivantamab-vmjw shows durable activity in subgroup of patients with advanced NSCLC
Patients with small cell lung cancer have ‘real choice’ in radiotherapy regimen
Pembrolizumab regimen extends OS in advanced malignant pleural mesothelioma
References:
Bogart J, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.01359.
Chi SA, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.2002.
Press Release
119 episodes
Share
